Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause
- Registration Number
- NCT02013544
- Lead Sponsor
- EndoCeutics Inc.
- Brief Summary
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on symptoms of vulvovaginal atrophy due to menopause and to collect further data on subjects exposed to intravaginal DHEA in order to meet the ICH E1 guideline requirements.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 558
Main criteria:
- Postmenopausal women (hysterectomized or not)
- Women between 40 and 80 years of age
- Women having ≤5% of superficial cells on vaginal smear at baseline
- Women having a vaginal pH above 5 at baseline
- Women who have self-identified moderate or severe symptom(s) of vaginal atrophy
- Willing to participate in the study and sign an informed consent
Main criteria:
- Previous enrollment in EndoCeutics studies performed with intravaginal DHEA
- Previous diagnosis of cancer, except skin cancer (non melanoma)
- Clinically significant metabolic or endocrine disease (including diabetes mellitus) not controlled by medication
- The administration of any investigational drug within 30 days of screening visit
- Clinically significant abnormal serum biochemistry, urinalysis or hematology
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Prasterone Prasterone (DHEA) Prasterone (DHEA) vaginal ovule daily for 12 weeks Placebo Placebo Placebo vaginal ovule daily for 12 weeks
- Primary Outcome Measures
Name Time Method Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia Baseline and Week 12 The severity of dyspareunia was evaluated by a questionnaire filled out by women. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Change From Baseline to Week 12 in Vaginal pH Baseline and Week 12 A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear Baseline and Week 12 The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear Baseline and Week 12 The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
- Secondary Outcome Measures
Name Time Method Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions Baseline and Week 12 To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color Baseline and Week 12 To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Change From Baseline to Week 12 in Severity of Vaginal Dryness Baseline and Week 12 The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness Baseline and Week 12 To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial surface thickness (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity Baseline and Week 12 To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.
Trial Locations
- Locations (38)
EndoCeutics site # 69
🇨🇦Corunna, Ontario, Canada
EndoCeutics site # 77
🇨🇦Quebec City, Quebec, Canada
EndoCeutics site # 04
🇨🇦Drummondville, Quebec, Canada
EndoCeutics site # 18
🇨🇦St-Romuald, Quebec, Canada
EndoCeutics site # 83
🇺🇸San Diego, California, United States
EndoCeutics site # 30
🇺🇸San Diego, California, United States
EndoCeutics site # 84
🇺🇸Corpus Christi, Texas, United States
EndoCeutics site # 80
🇺🇸West Palm Beach, Florida, United States
EndoCeutics site # 76
🇺🇸Seattle, Washington, United States
EndoCeutics site # 05
🇺🇸Cleveland, Ohio, United States
EndoCeutics site # 74
🇨🇦Sherbrooke, Quebec, Canada
EndoCeutics site # 15
🇺🇸Columbus, Ohio, United States
EndoCeutics site # 23
🇺🇸Atlanta, Georgia, United States
EndoCeutics site # 75
🇺🇸Philadelphia, Pennsylvania, United States
EndoCeutics site # 86
🇺🇸Louisville, Kentucky, United States
EndoCeutics site # 82
🇺🇸Houston, Texas, United States
EndoCeutics site # 03
🇺🇸Norfolk, Virginia, United States
EndoCeutics site # 36
🇺🇸Denver, Colorado, United States
EndoCeutics site # 55
🇺🇸Wichita, Kansas, United States
EndoCeutics site # 52
🇺🇸Denver, Colorado, United States
EndoCeutics site # 39
🇺🇸Montgomery, Alabama, United States
EndoCeutics site # 21
🇺🇸Sacramento, California, United States
EndoCeutics site # 14
🇺🇸Tucson, Arizona, United States
EndoCeutics site # 60
🇺🇸Lake Worth, Florida, United States
EndoCeutics site # 87
🇺🇸Lawrenceville, New Jersey, United States
EndoCeutics site # 01
🇨🇦Quebec City, Quebec, Canada
EndoCeutics site # 73
🇨🇦Waterloo, Ontario, Canada
EndoCeutics site # 45
🇺🇸Boynton Beach, Florida, United States
EndoCeutics site # 12
🇨🇦Montreal, Quebec, Canada
EndoCeutics site # 81
🇺🇸Plainsboro, New Jersey, United States
EndoCeutics site # 85
🇨🇦Burlington, Ontario, Canada
EndoCeutics site # 54
🇺🇸North Miami, Florida, United States
EndoCeutics site # 68
🇨🇦Sarnia, Ontario, Canada
EndoCeutics site # 67
🇨🇦Victoriaville, Quebec, Canada
EndoCeutics site # 27
🇺🇸Lutherville, Maryland, United States
EndoCeutics site # 02
🇨🇦Quebec City, Quebec, Canada
EndoCeutics site # 78
🇨🇦Quebec City, Quebec, Canada
EndoCeutics site # 79
🇨🇦Pointe-Claire, Quebec, Canada